These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24518525)

  • 1. The safety of erythropoiesis-stimulating agents in cancer patients.
    Leyland-Jones B
    Clin Adv Hematol Oncol; 2013; 11(9):596-7. PubMed ID: 24518525
    [No Abstract]   [Full Text] [Related]  

  • 2. [Erythropoiesis-stimulating agents: favorable safety profile when used as indicated].
    Adam M
    Strahlenther Onkol; 2008 Sep; 184(9):490. PubMed ID: 19016030
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I; Vansteenkiste J
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
    Lappin TR; Maxwell AP; Johnston PG
    Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 6. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 7. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoiesis-stimulating agents for anemic patients with cancer.
    Sheikh S; Littlewood TJ
    Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to "effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia".
    Coiffier B
    Oncologist; 2005 Oct; 10(9):762-3; author reply 764-5. PubMed ID: 16249359
    [No Abstract]   [Full Text] [Related]  

  • 12. Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
    Burstein HJ
    J Support Oncol; 2007 Apr; 5(4 Suppl 2):5-26. PubMed ID: 17550053
    [No Abstract]   [Full Text] [Related]  

  • 13. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J; Tonia T; Schwarzer G
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents.
    Gebara SN; Moubayed H
    J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-stimulating Agent Guidelines.
    Murray N; Klasa R
    J Clin Oncol; 2008 Jun; 26(18):3096-7. PubMed ID: 18565901
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies?
    Gupta G; Choi MJ
    Semin Dial; 2011; 24(4):379-81. PubMed ID: 21801225
    [No Abstract]   [Full Text] [Related]  

  • 17. Committee releases new guidelines on the use of erythropoiesis-stimulating agents.
    McBride D
    ONS Connect; 2011 Feb; 26(2):19. PubMed ID: 21388023
    [No Abstract]   [Full Text] [Related]  

  • 18. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anemia in cancer patients.
    Calabrich A; Katz A
    Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia.
    Schiavetto I; Pedrazzoli P; Basilico V; Siena S
    Chemotherapy; 2008; 54(6):417-20. PubMed ID: 18824846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.